The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
When Hillary Clinton announced that she wanted a big increase in Alzheimer’s research, she did it in typical Clinton fashion — with a major speech and a six-point plan, led by a specific commitment of $2 billion a year in federal funds to find a cure by 2025.
When Donald Trump announced his own support for Alzheimer’s research, he did it because someone asked him a question at a town hall. And his response was typical Trump. He assured the audience that Alzheimer’s was a “total top priority” for him, despite giving no specifics and no follow-up.
These are the two paths that US medical research could take now that the lineup for the November presidential election is settled. The fate of the Obama administration’s significant investments in biomedical research, from the Precision Medicine Initiative to the BRAIN Initiative, will end up in the hands of either a candidate with a long, wonky track record on health and medicine or the candidate whose views are an almost complete mystery.
Read full, original post: Clinton vs. Trump: A race between a policy wonk and a ‘black box’
